As a pediatric endocrinology fellow, Dr. Aikaterini (Katerina) Nella specializes in the diagnosis and treatment of all endocrine-related conditions of infants, children and adolescents.
10 Center Dr Room 1-3330, MSC 1103
Bethesda Md 20892-1103
For FedEx use:
Bethesda Md 20892
Topics in my portfolio:
Adrenal Gland Disorders
Children's Bone Health and Calcium
Congenital Adrenal Hyperplasia (CAH)
Obesity and Overweight
Pheochromocytoma and Paraganglioma
Polycystic Ovary Syndrome (PCOS)
Primary Ovarian Insufficiency (POI)
Puberty and Precocious Puberty
Dr. Aikaterini (Katerina) Nella received her medical degree with honors from the Aristotle University of Thessaloniki in Greece. She continued her post-graduate training in the United States and joined the University of Nebraska for a 2-year basic science research fellowship, studying the effects of oxidative stress on mitochondrial function. She completed a Pediatrics Residency at the combined Nebraska- Creighton Universities program and is certified by the American Board of Pediatrics. She joined the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) in 2011 as a Pediatric Endocrinology Clinical Fellow.
As a clinical fellow at the National Institute of Child Health and Human Development, Dr. Nella has expertise in the management of common pediatric endocrine diseases, such as pediatric diabetes, hypothyroidism, hyperthyroidism, hypopituitarism, growth failure, and congenital adrenal hyperplasia. She also treats rare pediatric endocrine disorders, such as Cushing disease and syndrome, congenital lipodystrophy, McCune Albright syndrome, congenital hypoparathyroidism, pheochromocytoma, multiple endocrine neoplasia syndromes, pediatric thyroid cancer, obesity syndromes such as WAGR, and rare rheumatologic syndromes such as CANDLE syndrome. Patients with these conditions come to NIH from all over the country and the world to receive high quality care and treatment.
Dr. Nella’s research spans over various aspects of pediatric endocrinology: “A pilot study assessing the use of continuous subcutaneous hydrocortisone infusion in the treatment of congenital adrenal hyperplasia” is a clinical study that will provide information on the safety and tolerability of hydrocortisone pump therapy in difficult-to-treat patients with congenital adrenal hyperplasia (CAH) and will compare the effectiveness of this technologically advanced therapy to standard oral glucocorticoid treatment. More details on this study can be found at http://www.nih.gov/news/health/jun2013/nichd-18.htm and clinicaltrials.gov.
Dr. Nella also studies “The growth factor Midkine as Tumor biomarker in Neurofibromatosis Type I”, which explores the role of the growth factor Midkine in children and young adults with Neurofibromatosis type I. She is an Associate Investigator in the research protocol “Detection and Treatment of Endocrine Abnormalities in Childhood Cancer Survivors”, which investigates the effects of cancer and cancer treatment on the endocrine glands of children, and the NICHD protocol "Endocrine studies in health and disease". Additionally, Dr. Nella works in the lab, exploring the role of microRNA-29 in the regulation of growth promoting genes.
Dr. Nella has been invited to present her research in many national and international conferences. She reviews manuscripts for the medical journals of Drug Metabolism Letters, PLos One and Journal of Clinical Endocrinology and Metabolism. She is a member of the American Academy of Pediatrics, the Society for Pediatric Research, the Pediatric Endocrine Society, the Endocrine Society and the American Medical Association. She is the fellow representative of the NICHD Pediatric Endocrinology Program and member of the NICHD Quality Assurance Committee.
|Relationship of 25-hydroxyvitamin D and asthma control in children.||Lewis E,Fernandez C,Nella A,Hopp R,Gallagher JC,Casale TB||Ann Allergy Asthma Immunol||2012 Apr|
|Chronically ischemic mouse skeletal muscle exhibits myopathy in association with mitochondrial dysfunction and oxidative damage.||Pipinos II,Swanson SA,Zhu Z,Nella AA,Weiss DJ,Gutti TL,McComb RD,Baxter BT,Lynch TG,Casale GP||Am J Physiol Regul Integr Comp Physiol||2008 Jul|
|The myopathy of peripheral arterial occlusive disease: Part 2. Oxidative stress, neuropathy, and shift in muscle fiber type.||Pipinos II,Judge AR,Selsby JT,Zhu Z,Swanson SA,Nella AA,Dodd SL||Vasc Endovascular Surg||2008 Apr-May|
|The myopathy of peripheral arterial occlusive disease: part 1. Functional and histomorphological changes and evidence for mitochondrial dysfunction.||Pipinos II,Judge AR,Selsby JT,Zhu Z,Swanson SA,Nella AA,Dodd SL||Vasc Endovascular Surg||2007 Dec-2008 Jan|
|Mitochondriopathy of peripheral arterial disease.||Makris KI,Nella AA,Zhu Z,Swanson SA,Casale GP,Gutti TL,Judge AR,Pipinos II||Vascular||2007 Nov-Dec|